Stoke Therapeutics Inc (STOK)
Stoke Therapeutics Inc (STOK) is a NASDAQ-listed common stock in the healthcare sector and biotechnology industry. The security is a common equity listing for a company that works on therapies for severe genetic diseases. Its research centers on approaches designed to increase the production of specific proteins that may be missing or reduced in certain conditions. As a listed biotech equity, STOK reflects the market view of the company’s development-stage work, clinical progress, and broader funding needs. This overview describes the security itself on the NASDAQ exchange rather than making claims about investment performance or business outcomes.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-STOK
|
$24.09
|
-17.5% Downside
|
Fair
|
$46.46
|
59.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
5.5x
|
68.3x
|
1.884 B
|
1.533 B
|
0.1%
|
76.3%
|
19.3
|
86.9%
|